ArticleApplied biochemistry and biotechnology2026
Investigating the Effects of a CCR3 Antagonist and SP-A Eosinophil Suppressor Tetrapeptide-Transduced Mesenchymal Stem Cells in Allergic Asthma.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic asthma (AA) is a consequential global health challenge immunologically characterized by type 2 inflammatory responses and no definite treatment, demanding novel therapeutic strategies. Eosinophils are the main orchestration of AA, whose recruitment and activation depends on C-C chemokine receptor type 3 (CCR3). Genetically engineered stem cells present enhanced therapeutic efficacy and a compelling strategy to control diseases. Therefore, this study was conducted to investigate the effects of a CCR3 antagonist and genetically engineered mesenchymal stem cells (MSCs) on AA progression in mice models. MSCs were isolated from bone marrow and transduced by SP-A and RGDS genes. Mice with induced AA were treated with the CCR3 antagonist and modified MSCs, and then pathologic features, including AHR, percentage of eosinophil in BALF, levels of SOD and CAT (oxidative stress biomarkers), total and OVA-specific IgE, IL-4, IL-5, IL-13, and IL-33, as well as histopathology of the lung for peribronchial and perivascular inflammation, hyperplasia of the goblet cells, and overproduction of mucus were assessed. SP-A and RGDS transduced MSCs combined with the CCR3 antagonist effectively reverted AHR, eosinophil infiltration into BALF, elevation of IgE and Th2 cytokines, and histopathological derangements associated with AA, along with enhanced activity of CAT and SOD. Altogether, genetically modified MSCs in combination with a CCR3 antagonist could control AA progression biomarkers.
Indexed as
Identifiers
42825860What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.